Recombinant DNA (rDNA) Technology Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| CAGR | 6.80 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Recombinant DNA (rDNA) Technology Market Analysis
The recombinant DNA (rDNA) technology market is projected to register a CAGR of 6.8% during the forecast period (2022-2027).
The COVID-19 pandemic had a positive impact on the market studied, as it increased the demand for recombinant DNA technology in the development of therapeutics and diagnostics. For instance, in November 2020, a research paper published in the United States National Library of Medicine titled "Recombinant vaccines for COVID-19" stated that the recombinant COVID-19 vaccine can overcome limitations and the safety concerns associated with other vaccines. Moreover, many COVID-19 vaccines have been manufactured by several companies based on recombinant DNA technology. Likewise, as per the article titled "A review on Promising vaccine development progress for COVID-19 disease" published in November 2020 in the National Library of Medicine, the COVID-19 vaccines are being developed using cutting-edge recombinant technology, in addition, to live vectored and inactivated viruses. Hence, such factors are ultimately boosting the demand for recombinant DNA technology in developing vaccines for COVID-19, thereby boosting the market growth over the coming years.
Recombinant DNA technology (RDT) is essential for improving health conditions, primarily by developing new vaccines and pharmaceuticals. Moreover, the treatment strategies are improved by developing diagnostics kits, monitoring devices, and new therapeutic approaches. Additionally, many other industries are benefiting from the research conducted on genetically modified organisms (GMOs), such as microorganisms that are considered clean fuel producers and biodegraders. Genetically modified vaccines are developed to cure various diseases in humans and plants. Recombinant DNA technology has created several potential innovation opportunities for developing a wide range of therapeutic products with immediate effect in medical genetics and biomedicine by modifying microorganisms, animals, and plants to yield medically useful substances.
Product launches are another factor accelerating the growth of the market. For instance, in September 2021, a Tokyo-based start-up called Sanatech Seed Co. teamed up with scientists at the University of Tsukuba to develop a new variety of tomatoes with the help of CRISPR/Cas9 gene-editing technology. The first products offered were seeds, delivered free of charge to around 4,200 people. The company has started selling genetically modified tomatoes. Such launches will increase the growth of the market in the coming future.
Thus, the increasing demand and application of RDT in various sectors are driving the growth of the market studied. However, regulatory, scientific, and ethical challenges associated with rDNA technology and gene therapy may restrain the growth of the market.
Recombinant DNA (rDNA) Technology Market Trends
This section covers the major market trends shaping the Recombinant DNA (rDNA) Technology Market according to our research experts:
The Food and Agriculture Segment is Expected to Register the High CAGR Over the Forecast Period
In agriculture, the development of genetically modified crops, to improve both yield and resistance to pests or herbicides, is gaining a high degree of public acceptance. The genetically modified tomato, CGN-89564-2, was one of the first commercially grown, genetically engineered crop products to be granted a license for human consumption. Additionally, DNA molecular marker technology is important for the preservation, identification, evaluation, mining, and innovation of plant germplasm resources.
The introduction of genetically modified fruit paved the way for the use of GMOs in food. Currently, genetic modification is witnessing widespread adoption. Similarly, China plans an overhaul of its seed rules that will pave the way for GMO approvals. It is a big step for China's modern agriculture and a new business opportunity for upstream agriculture input suppliers. In July 2021, the 20th meeting of the Commission for Deepening Overall Reform of the China Central Committee deliberated and approved the "Action Plan for Revitalizing the Seed Industry." The plan provides insight into China, showing the significant importance of the innovations brought on by biological breeding, especially the R&D and industrialization of genetically modified organisms (GMO). Due to these approvals, the segment is likely to grow in the future.
Initiatives by public and private organizations are one of the key drivers of the growth of the segment. For instance, in August 2021, Corteva Inc. launched a genetically modified Conkesta E3 soybean seed in the Brazilian market. The soybeans recently received authorization by the European Union Commission, which enables grain produced from Conkesta E3 soybean seeds grown in Brazil to be exported to the European market for food and feed use.
Thus, increasing the application of RDT in agriculture and food is expected to drive the growth of the segment studied.
North America is Expected to Dominate the Market Over the Forecast Period
The North American region is expected to dominate the market studied over the forecast period. In the North American region, the United States accounts for the largest market share, primarily due to the presence of numerous biopharmaceutical manufacturing companies and the presence of effective regulatory bodies to monitor the various ethical and scientific concerns about the use of technology. This is expected to drive the market's growth, especially in North America.
Various research studies are leading to the growth of the market. For instance, in September 2021, a research study published in the United States National Library of Medicine titled "Review of Poultry Recombinant Vector Vaccines" stated that the control of poultry diseases relies heavily on the use of many live and inactivated vaccines. Moreover, over the last 30 years, recombinant DNA technology has been used to generate many novel poultry vaccines. Fowlpox virus and turkey herpesvirus are the two main vectors currently used to construct recombinant vaccines for poultry. With the use of these two vectors, more than 15 recombinant viral vector vaccines against Newcastle disease, infectious laryngotracheitis, infectious bursal disease, avian influenza, and Mycoplasma gallisepticum have been developed and are commercially available. With the increasing research studies to support vaccine development, the market is likely to grow in the near future.
Additionally, in May 2022, PharmaJet reported that its partner, the Institute for Molecular Medicine (IMM), had received an award of USD 12 million from the National Institute on Aging (NIA) division of the National Institutes of Health (NIH). The grant supports clinical trials of the beta-amyloid vaccines based on DNA and recombinant proteins for the prevention of Alzheimer's disease (AD). Such research studies are propelling the growth of the market.
Hence, due to the above-mentioned factors, the market is likely to grow in the future, and North America is likely to dominate the market.
Recombinant DNA (rDNA) Technology Industry Overview
The Recombinant DNA (rDNA) Technology market is competitive, with the presence of both major players and small players. In terms of market share, the major players are currently dominating the market. Some of the major market players include GenScript, New England Biolabs, GlaxoSmithKline PLC, Pfizer, and Sanofi, among others.
Recombinant DNA (rDNA) Technology Market Leaders
-
New England Biolabs
-
GlaxoSmithKline plc
-
Pfizer
-
Sanofi
-
GenScript
*Disclaimer: Major Players sorted in no particular order
Recombinant DNA (rDNA) Technology Market News
- In March 2022, VBI Vaccines Inc. launched PreHevbrio (Recombinant Hepatitis B Vaccine) in the United States for the prevention of infection caused by all known subtypes of hepatitis B virus (HBV) in adults age 18 years and older.
- In February 2022, VBI Vaccines Inc. received the European Medicines Agency's Committee for Medicinal Products for Human Use's positive opinion for VBI's 3-antigen hepatitis B (HBV) vaccine, under the brand name PreHevbri, for active immunization against infection caused by all known subtypes of the hepatitis B virus in adults.
Recombinant DNA (rDNA) Technology Market Report - Table of Contents
1. INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Technological Advancements in Genomics
4.2.2 Expansion of Biopharmaceutical Industry
4.2.3 Increasing Demand and Applications of Recombinant/ Genetically Modified Products
4.3 Market Restraints
4.3.1 Regulatory, Scientific, and Ethical Challenges Associated with Gene Therapy
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD million)
5.1 By Product
5.1.1 Medical
5.1.1.1 Therapeutic Agent
5.1.1.2 Human Protein
5.1.1.3 Vaccine
5.1.2 Non-medical
5.1.2.1 Biotech Crops
5.1.2.2 Specialty Chemicals
5.1.2.3 Other Non-medical Products
5.2 By Component
5.2.1 Expression System
5.2.2 Cloning Vector
5.3 By Application
5.3.1 Food and Agriculture
5.3.2 Health and Disease
5.3.3 Environment
5.3.4 Other Applications
5.4 By End User
5.4.1 Biotechnology and Pharmaceutical Companies
5.4.2 Academic and Government Research Institutes
5.4.3 Other End Users
5.5 Geography
5.5.1 North America
5.5.1.1 United States
5.5.1.2 Canada
5.5.1.3 Mexico
5.5.2 Europe
5.5.2.1 Germany
5.5.2.2 United Kingdom
5.5.2.3 France
5.5.2.4 Italy
5.5.2.5 Spain
5.5.2.6 Rest of Europe
5.5.3 Asia-Pacific
5.5.3.1 China
5.5.3.2 Japan
5.5.3.3 India
5.5.3.4 Australia
5.5.3.5 South korea
5.5.3.6 Rest of Asia-Pacific
5.5.4 Middle East and Africa
5.5.4.1 GCC
5.5.4.2 South Africa
5.5.4.3 Rest of Middle East and Africa
5.5.5 South America
5.5.5.1 Brazil
5.5.5.2 Argentina
5.5.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Amgen Inc.
6.1.2 Eli Lilly and Company
6.1.3 F. Hoffmann-La Roche Ltd (Genentech Inc.)
6.1.4 GenScript
6.1.5 Horizon Discovery
6.1.6 Merck KGaA
6.1.7 New England Biolabs
6.1.8 Novartis AG
6.1.9 Novo Nordisk A/S
6.1.10 Pfizer Inc.
6.1.11 Sanofi
6.1.12 Syngene International Limited
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
Recombinant DNA (rDNA) Technology Industry Segmentation
As per the scope of the report, recombinant DNA technology is a process in which the creation and manipulation of DNA sequences are done in a specific order, resulting in the production of genetically modified organisms and products. Recombinant DNA is primarily used in conventional and non-conventional applications, such as medicinal, agricultural, and industrial. In medicine, recombinant DNA has been used for the mass production of insulin, Follistim, human growth hormones, monoclonal antibodies, human albumin, vaccines, and other drugs. The recombinant DNA (rDNA) technology market is segmented by product (medical (therapeutic agent, human protein, and vaccine), non-medical (biotech crops, specialty chemicals, and other non-medical products), component (expression system, and cloning vector), application (food and agriculture, health and disease, environment, and other applications), end user (biotechnology and pharmaceutical companies, academic and government research institutes, and other end users), and geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions globally. The report offers the value (in USD million) for the above-mentioned segments.
| By Product | |||||
| |||||
|
| By Component | |
| Expression System | |
| Cloning Vector |
| By Application | |
| Food and Agriculture | |
| Health and Disease | |
| Environment | |
| Other Applications |
| By End User | |
| Biotechnology and Pharmaceutical Companies | |
| Academic and Government Research Institutes | |
| Other End Users |
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Recombinant DNA (rDNA) Technology Market Research FAQs
What is the current Global Recombinant DNA (rDNA) Technology Market size?
The Global Recombinant DNA (rDNA) Technology Market is projected to register a CAGR of 6.80% during the forecast period (2024-2029)
Who are the key players in Global Recombinant DNA (rDNA) Technology Market?
New England Biolabs, GlaxoSmithKline plc, Pfizer, Sanofi and GenScript are the major companies operating in the Global Recombinant DNA (rDNA) Technology Market.
Which is the fastest growing region in Global Recombinant DNA (rDNA) Technology Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Global Recombinant DNA (rDNA) Technology Market?
In 2024, the North America accounts for the largest market share in Global Recombinant DNA (rDNA) Technology Market.
What years does this Global Recombinant DNA (rDNA) Technology Market cover?
The report covers the Global Recombinant DNA (rDNA) Technology Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Global Recombinant DNA (rDNA) Technology Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Recombinant DNA Technology Industry Report
Statistics for the 2024 Recombinant DNA Technology market share, size and revenue growth rate, created by Mordor Intelligenceā¢ Industry Reports. Recombinant DNA Technology analysis includes a market forecast outlook 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
